Armata Pharmaceuticals, Inc. (ARMP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Marina del Rey, CA, United States. The current CEO is Deborah L. Birx.
ARMP has IPO date of 1994-05-20, 60 full-time employees, listed on the American Stock Excha, a market capitalization of $471.83M.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
